The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

Daniele Focosi, Albert Farrugia

Research output: Contribution to journalShort survey

2 Citations (Scopus)

Abstract

COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.

Original languageEnglish
Pages (from-to)244-246
Number of pages3
JournalInternational Journal of Infectious Diseases
Volume102
DOIs
Publication statusPublished - Jan 2021

Fingerprint Dive into the research topics of 'The art of the possible in approaching efficacy trials for COVID19 convalescent plasma'. Together they form a unique fingerprint.

Cite this